Update on anti-CTLA-4 antibodies in clinical trials
Expert Opinion on Biological TherapyPublished 1 August 2007
Lee Langer, Timothy M. Clay, Michael A. Morse
Citations76
SJR quartileQ1
SJR score1.15
SNIP0.89
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events are reviewed.
Abstract
Breaking immune tolerance against tumor self-antigens is presently an area of intense research in the design of cancer therapies. One possible method to enhance immune system activation against tumor antigens is by blocking the inhibitory co-stimulatory signals mediated by cytotoxic T lymphocyte antigen 4, (CTLA-4) expressed on activated T cells. The fully human monoclonal antibodies that are directed against human CTLA-4, ipilimumab (Medarex/Bristol-Myers Squibb) and CP-675,206 (Pfizer/Abgenix, now Amgen), have demonstrated activity against metastatic melanoma, hormone refractory prostate cancer and other malignancies. They have also uncovered unusual immune-related adverse events manifesting as self-limiting inflammatory reactions of the bowel, skin and pituitary. This article reviews preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events.
Keywords
Immunology and MicrobiologyMedicine
ScienceEnhancement of Antitumor Immunity by CTLA-4 Blockade
3,918 Citations1996Dana R. Leach, Matthew F. Krummel +1 more
In vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors, and this rejection resulted in immunity to a secondary exposure to tumor cells, suggesting that blockade of the inhibitory effects of CTLA4 can allow for, and potentiate, effective immune responses against tumor cells.
ImmunityLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
2,896 Citations1995Elizabeth Tivol, Frank Borriello +4 more
The phenotype of the CTLA-4-deficient mouse strain implies a critical role for CTla-4 in down-regulating T cell activation and maintaining immunologic homeostasis.
ScienceLymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>
2,755 Citations1995Paul Waterhouse, Josef Penninger +7 more
Although CTLA-4-deficient T cells proliferated spontaneously and strongly when stimulated through the T cell receptor, they were sensitive to cell death induced by cross-linking of the Fas receptor and by gamma irradiation, and is vital for the control of lymphocyte homeostasis.
Proceedings of the National Academy of SciencesCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
1,573 Citations2003Giao Q. Phan, James Chih‐Hsin Yang +15 more
This study establishes CTLA-4 as an important molecule regulating tolerance to “self” antigens in humans and suggests a role for CTla-4 blockade in breaking tolerance to human cancer antIGens for cancer immunotherapy.
The Journal of Experimental MedicineCombination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
1,015 Citations1999Andrea van Elsas, Arthur A. Hurwitz +1 more
This study shows that CTLA-4 blockade provides a powerful tool to enhance T cell activation and memory against a poorly immunogenic spontaneous murine tumor and that this may involve recruitment of autoreactive T cells.
Journal of Clinical OncologyAutoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
1,013 Citations2005Peter Attia, Giao Q. Phan +15 more
Administration of anti-CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.
Annual Review of ImmunologyComplexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation
1,007 Citations2001Benoı̂t L. Salomon, Jeffrey A. Bluestone
Evidence is presented that suggests that multiple mechanisms contribute to CD28/B7-mediated T cell costimulation in disease settings that include expansion of activated pathogenic T cells, differentiation of Th1/Th2 cells, and the migration of T cells into target tissues.
Journal of Clinical OncologyEnterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
834 Citations2006Kimberly E Beck, Joseph Blansfield +13 more
CTLA4 seems to be a significant component of tolerance to tumor and in protection against immune mediated enterocolitis and these phenomena are significantly associated in cancer patients.
ImmunityInduction of Peripheral T Cell Tolerance In Vivo Requires CTLA-4 Engagement
711 Citations1997Víctor Pérez, Luk Van Parijs +4 more
It is shown that the induction of T cell anergy in vivo is due to an abortive T cell response that requires recognition of B7 molecules, since blocking B7 maintains T cells in an unactivated but functionally competent state.
Journal of Clinical OncologyAntitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
584 Citations2005Antoni Ribas, Luis H. Camacho +11 more
CP-675,206 can be administered safely to humans as a single IV dose up to 15 mg/kg, resulting in breaking of peripheral immune tolerance to self-tissues and antitumor activity in melanoma.
Annals of Surgical OncologyTumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
491 Citations2005Ajay V. Maker, Giao Q. Phan +12 more
There is not evidence to support a synergistic effect of CTLA-4 blockade plus IL-2 administration, because the 22% objective response rate is that expected from the sum of these two agents administered alone.
Current Opinion in ImmunologyPrinciples and use of anti-CTLA4 antibody in human cancer immunotherapy
442 Citations2006Karl S. Peggs, Sergio A. Quezada +2 more
Following extensive preclinical modeling, these agents have entered clinical trials, where they are showing encouraging activity in heavily pretreated patients with advanced-stage disease, particularly with melanoma or renal carcinoma.
Journal of Clinical OncologyAutoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma
433 Citations2004Kristin M. Sanderson, Ronald Scotland +10 more
Dose-related autoimmune adverse events, predominantly skin and GI toxicities, were reversible and patients mounted an antigen-specific immune response to a peptide vaccine when combined with a human anti-CTLA-4 antibody.
PubMedCombination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
427 Citations2000Arthur A. Hurwitz, Barbara A. Foster +6 more
It is demonstrated that an effective immune response against primary prostate tumors in transgenic (TRAMP) mice can be elicited using a strategy that combines CTLA-4 blockade and an irradiated tumor cell vaccine, and suggest potential of this approach for treatment of prostate cancer.
ImmunityLymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells
415 Citations1997Cynthia A. Chambers, Timothy J. Sullivan +1 more
It is demonstrated that there is a preferential expansion of CD4+ T cells in CTLA-4(-/-) mice, which results in a skewing of the CD4/CD8 T cell ratio, which suggests that the role of CTla-4 in peripheral CD4- versus CD8+ T cell homeostasis is distinct.
Clinical Cancer ResearchA Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
406 Citations2007Eric J. Small, N. Simon Tchekmedyian +4 more
A single dose of 3 mg/kg Ipilimumab, an anti-CTLA-4 antibody, given to patients with prostate cancer is safe and does not result in significant clinical autoimmunity.
Proceedings of the National Academy of SciencesManipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
393 Citations1997Eugene D. Kwon, Arthur A. Hurwitz +6 more
A novel syngeneic murine prostate cancer model is established and in vivo antibody-mediated blockade of CTLA-4 enhances antiprostate cancer immune responses, suggesting that appropriate manipulation of T cell costimulatory and inhibitory signals may provide a fundamental and highly adaptable basis for prostate cancer immunotherapy.
Proceedings of the National Academy of SciencesCTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
374 Citations1998Arthur A. Hurwitz, Tina F.-Y. Yu +2 more
The combination of both CTLA-4 blockade and a vaccine consisting of granulocyte-macrophage colony-stimulating factor-expressing SM1 cells resulted in regression of parental SM1 tumors, despite the ineffectiveness of either treatment alone.
The Journal of Experimental MedicineElucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
307 Citations2001Andrea van Elsas, Roger P.M. Sutmuller +9 more
The data demonstrate that therapeutic autoreactive CD8+ T cell responses can effectively be generated in tumor-bearing mice and stresses the value of studying tumor immunity in a therapeutic rather than a prophylactic setting.
Nature ImmunologyThe nature of molecular recognition by T cells
227 Citations2003Simon J. Davis, Shinji Ikemizu +4 more
Developments in characterizing four key sets of interactions controlling antigen responsiveness in T cells are reviewed and the major challenges remaining as the field moves toward formulating quantitative models of T cell recognition are highlighted.
Proceedings of the National Academy of SciencesElimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
223 Citations1999Eugene D. Kwon, Barbara A. Foster +5 more
The potential of adjunctive CTLA-4 blockade immunotherapy to reduce cancer relapse emanating from minimal residual metastatic disease is demonstrated and may have broader implications for improving the capability of immunotherapy by combining such forms of therapy with other cytoreductive measures including surgery.
PubMedMultivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.
189 Citations2003Sandra Santulli-Marotto, Smita K. Nair +3 more
The development of RNA aptamers that bind CTLA-4 with high affinity and specificity are described and it is demonstrated that aptamer can be used to manipulate the immune system for therapeutic applications and that multivalent versions ofaptamers may be particularly potent agents in vivo.
CancerBiologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma
144 Citations2006James M. Reuben, Bang‐Ning Lee +8 more
The immunobiologic effects of ticilimumab, a human monoclonal antibody against CTLA‐4, was administered to patients with metastatic melanoma who participated in a Phase I/II clinical trial.
The Journal of ImmunologyActivity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
132 Citations2003Tibor Keler, Ed Halk +9 more
Observations support the development of CTLA-4 blockade for human immunotherapy and banishes the possibility of monkey anti-human Ab responses in the monkeys.
Journal of Clinical OncologyImmunotherapy for Renal Cell Cancer
105 Citations2006James C. Yang, Richard Childs
It is clear that renal cancer remains one of the most immunoresponsive of human malignancies and that advances in immune modulation are again translating into clinical responses for patients with this disease.
The Journal of ImmunologyCTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model
78 Citations2003Jonathan Espenschied, Jeffrey Lamont +5 more
The potential of a novel cell-free vaccine targeting p53 in malignancy is demonstrated, and in vivo Ab depletion confirmed that the antitumor effect was primarily CD8 and to a lesser extent CD4 dependent.
Journal of Clinical OncologyRandomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer
69 Citations2006Eric J. Small, Celestia S. Higano +8 more
Ipilimumab was well tolerated in this group of pts with HRPC and there was no apparent enhancement of activity by coadministration of a single dose of docetaxel.
The Journal of Experimental MedicineModulation of Susceptibility to HIV-1 Infection by the Cytotoxic T Lymphocyte Antigen 4 Costimulatory Molecule
54 Citations1999James L. Riley, Katia Schlienger +6 more
It is shown that cytotoxic T lymphocyte antigen 4 (CTLA- 4) engagement counteracts the CD28 antiviral effects, and that the ratio of CTLA-4 to CD28 engagement determines the susceptibility of HIV-1 infection.
Journal of Clinical OncologyDurable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma
49 Citations2005Steven Fischkoff, E. M. Hersh +8 more
Long-term follow-up data on response duration and median progression-free survival for this Phase II study is now reported.
PubMedTechnology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
48 Citations2005Michael A. Morse
Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.
The Journal of ImmunologyCTLA-4 Differentially Regulates T Cell Responses to Endogenous Tissue Protein Versus Exogenous Immunogen
41 Citations2002Lucy S. K. Walker, Lara J. Ausubel +3 more
Infection and ImmunityCTLA-4 Down-Regulates the Protective Anticryptococcal Cell-Mediated Immune Response
41 Citations2000Tracy L. McGaha, J W Murphy
The data indicate that blockade of CTLA-4 interactions with its ligands may be useful in enhancing host defenses againstC.
The Journal of Infectious DiseasesUnresponsive CD4<sup>+</sup>T Lymphocytes from<i>Leishmania chagasi</i>–Infected Mice Increase Cytokine Production and Mediate Parasite Killing after Blockade of B7‐1/CTLA‐4 Molecular Pathway
40 Citations1998Nitza A. Gomes, Victor Barreto‐de‐Souza +2 more
CTLA-4 engagement by B7-1 plays an important role in maintaining unresponsiveness in CD4+ T cells in this model of chronic visceral leishmaniasis, and CTLA-3 blockade completely restored activation-induced interleukin-2 secretion and increased interferon-gamma production.
Journal of Clinical OncologyTumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010)
40 Citations2005James C. Yang, Kayla Beck +4 more
Patients with advanced renal cancer were given MDX-010, a human IgG1 antibody to CTLA4 every 3 weeks to unbalance this antagonistic network in favor of lymphocyte activation and toxicities were primarily autoimmune.
Journal of Clinical OncologyPhase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma
39 Citations2006Jeffrey S. Weber, Ş. Targan +6 more
The data suggest that IBEs are associated with clinical benefit in patients with resected high-risk melanoma receiving Ipilimumab at 3 mg/kg with a peptide vaccine, and support testing the current regimen in a larger randomized trial.
Cancer ResearchPreclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.
37 Citations2004Douglas C. Hanson, Paul C. Canniff +13 more
All experiments unequivocally demonstrated that OTP-001 has significant antitumor effect after systemic administration in mice with transplanted B16, T241 or Lewis lung tumors and the dose-limiting toxicity appears to be due to mucosal reactions in the gut.
Journal of Clinical OncologyPhase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma
31 Citations2005Antoni Ribas, Viviana Bozón +8 more
The safety, tolerability and recommended phase II dose of Monthly CP-675,206 was assessed in this study and preliminary PK analysis suggests little accumulation of the drug with multiple dosin...
Journal of Clinical OncologySurvival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study
20 Citations2007Jesús Gómez-Navarro, Scott Antonia +8 more
A multidose phase I/II trial of the fully human anti-CTLA4 mAb CP-675,206 in pts with metastatic melanoma found that prolonged survival was observed in a prior single-dose phase I study, even in pts who did not achieve objective tumor responses.
Journal of Clinical OncologyPhase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies
18 Citations2004Luis H. Camacho, A. Ribas +8 more
CTLA4 blockade can be induced with a single injection of CP-675,206 and related autoimmunity is reversible, and observed anti-tumor activity may be associated with breaking peripheral tolerance through this mechanism.
Journal of Clinical OncologyA phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma
13 Citations2004E. M. Hersh, Jeffrey S. Weber +7 more
It is suggested that combination therapy with dacarbazine may have greater clinical activity than monotherapy in patients with Stage IV melanoma and could break tolerance and induce organ specific autoimmunity.
Journal of Clinical OncologyTherapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM)
12 Citations2005James M. Reuben, B. N. Lee +8 more
T-regulatory cells are CD3+CD4+CD25+ and produce IL-10 and engagement of CTLA-4 on activated T cells with CD80/CD86 on APC diminishes T-cell activation and proliferation.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4
9 Citations2005Peter Attia, Phan Q Giao +2 more
Administration of anti-CTLA-4 monoclonal antibody, plus peptide vaccination, can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.
Journal of Clinical OncologyA phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum
6 Citations2007Ki Y. Chung, Ira Gore +6 more
The purpose of this study was to assess safety and efficacy of CTLA4 blockade with the fully human mAb CP-675,206 as single-agent therapy in pts with relapsed/ refractory colorectal cancer.
Journal of Clinical OncologyAntigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab
6 Citations2006Antoni Ribas, B. Comin-Anduix +9 more
Ticilimumab administered monthly induces immune-related phenomena and tumor responses in patients with melanoma without a demonstrable expansion of circulating melanoma antigen-specific T cells.
Journal of Clinical Oncology<i>Ex vivo</i> blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206)
4 Citations2006Robert Millham, Dmitri Pavlov +6 more
The SEA assay provides a functional assessment of ticilimumab activity and can be used to guide the clinical development of this agent, and suggests that T cell reactivity is enhanced in the presence of tICilimumAB in vitro, in primate models and in humans.
PubMedPhage Display Technologies - SMi Conference. 23-24 January 2002, London, UK.
1 Citations2002Lutz Jermutus
This fairly small meeting, with about 50 attendees, covered all areas of antibody engineering from basic technologies to applications in both therapeutic and diagnostic areas and the data presented were solid and highly informative.